Herbal Remedies

  Education ToolBox

  CERT Publications

 
 
Arizona Health Sciences Center
     ©2002 Arizona CERT
    

 

Browse Drug List


Drugs That Prolong the Q-T Interval and/or Induce Torsades de Pointes
Raymond L. Woosley, MD, PhD

Information from the medical literature, the FDA-approved drug labeling and reports submitted to the FDA Adverse Events Reporting System database.

  Browse by clicking on the first letter of the drug's brand or generic name:

A · B · C · D · E · F · G · H · I · J · K · L · M


N · O · P · Q · R · S · T · U · V · W · X · Y · Z
Search by keyword(s):
 
Generic Name Dopamine More Info
Brand Name(s) Intropine®
Drug Class Anti-arrhythmic
QT
TdP
Risk Group A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome.
Comments

   
   



Generic Name Droperidol More Info
Brand Name(s) Inapsine®
Drug Class Sedative;Anti-nausea
QT
QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug.
TdP
The FDA-approved labeling includes mention of cases or a risk of Torsades de Pointes.
Risk Group A drug that is generally accepted by authorities to have a risk of causing Torsades de Pointes. This drug should be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome.
Comments
There are case reports of Torsades de Pointes in the medical literature.
   
   



Generic Name Ibutilide More Info
Brand Name(s) Corvert®
Drug Class Anti-arrhythmic
QT
QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug.
TdP
The FDA-approved labeling includes mention of cases or a risk of Torsades de Pointes.
Risk Group A drug that is generally accepted by authorities to have a risk of causing Torsades de Pointes. This drug should be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome.
Comments
Substantial evidence indicates a greater risk of Torsades de Pointes in women.
Females>Males
   
   



Generic Name Imipramine More Info
Brand Name(s) Norfranil®
Drug Class Tricyclic Antidepressant
QT
TdP
Risk Group A drug that, in some reports, has been weakly associated with Torsades de Pointes but that, when used in usual dosages, is unlikely to be a risk for Torsades de Pointes.
Comments

   
   



Generic Name Indapamide More Info
Brand Name(s) Lozol®
Drug Class Diuretic
QT
QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug.
TdP
Risk Group A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome.
Comments
There are case reports of Torsades de Pointes in the medical literature.
   
   



Generic Name Isoproterenol More Info
Brand Name(s) Isupres®,Medihaler-Iso®
Drug Class Catecholamine
QT
TdP
Risk Group A drug to be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome.
Comments

   
   



Generic Name Isradipine More Info
Brand Name(s) Dynacirc®
Drug Class Anti-hypertensive
QT
QT prolongation is mentioned in the FDA-approved labeling as a known action of the drug.
TdP
Risk Group A drug that may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. This drug should be avoided for use in patients with diagnosed or suspected Congenital Long QT Syndrome.
Comments

   
   



Generic Name Itraconazole More Info
Brand Name(s) Sporanox®
Drug Class Anti-fungal
QT
TdP
Risk Group A drug that, in some reports, has been weakly associated with Torsades de Pointes but that, when used in usual dosages, is unlikely to be a risk for Torsades de Pointes.
Comments

   
   



  A note about Brand Names: Drugs are listed with up to 2 common brand names. There are many more brand names for some of the common drugs, such as pseudoephedrine and erythromycin. It is also important to look at the list of active drugs in medicines that contain a combination of drugs such as Zyrtec-D®, which contains pseudoephedrine.
 
 

The University of Arizona Center for Education and Research on Therapeutics
Arizona Health Sciences Center
Tucson, Arizona 85724-5018

Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385-01

Disclaimer and Waiver
The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases the University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.

Information Center For Consumers Arizona CERT Home For Professionals